Shenzhen Xinlitai Pharmaceutical Co., Ltd. was established in 1998 and listed on the Shenzhen Stock Exchange in 2009 (stock code: 002294). It is a comprehensive pharmaceutical group integrating the research and development, production and sales of pharmaceutical products.

With high-quality innovative products and evidence-based medicine promotion as the core competitiveness, the company maintains its leading position in high-end cardiovascular and cerebrovascular medicines, while expanding target areas such as blood sugar reduction, anti-tumor, orthopedics and anti-infection, through independent research and development, technical cooperation and mergers and acquisitions. and other channels to quickly enrich product pipelines, develop multiple major products, and jointly build a pharmaceutical ecological chain.
The company has been deeply engaged in the cardiovascular and cerebrovascular field for many years, and has anti-small plate drugs "Taijia" and "Taiyi", anticoagulant drug "Taiganin", ARB antihypertensive new drugs "Xinlitan" and "Alpha" Many major products such as drug-eluting coronary stents have formed a complete product layout that combines medicine and equipment, providing better comprehensive solutions for the majority of patients.

The company accurately deploys the global industrial chain, and its business scope covers more than 30 countries and regions including China, the United States, Germany, France, and Japan.